{"id":212,"date":"2013-02-08T15:45:34","date_gmt":"2013-02-08T20:45:34","guid":{"rendered":"http:\/\/licensinglaw.net\/blog3\/?page_id=212"},"modified":"2021-04-12T09:49:12","modified_gmt":"2021-04-12T13:49:12","slug":"f2o-prosecution","status":"publish","type":"page","link":"https:\/\/licensinglaw.net\/blog3\/?page_id=212","title":{"rendered":"&#8220;F2O Prosecution&#8221;"},"content":{"rendered":"<p style=\"text-align: justify;\">Have you identified a pending third party patent application which threatens to derail an important new product launch?\u00a0 Perhaps we can help twice over, negating the legal threat of infringement while also increasing your market share.\u00a0 We call this \u201cF2O Prosecution\u201d because it fills two goals at once \u2013 providing freedom to operate <i>viz<\/i> the pending third party application, while at the same time protecting your own market share as good quality prosecution should do.\u00a0 While not easy to execute, the results can be impressive.\u00a0 Here\u2019s an example:<\/p>\n<p style=\"text-align: justify;\"><a href=\"https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/AHER-2007-US7186842B2-Zoomed-scaled.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft wp-image-842 size-medium\" src=\"https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/AHER-2007-US7186842B2-Zoomed-300x170.jpg\" alt=\"\" width=\"300\" height=\"170\" srcset=\"https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/AHER-2007-US7186842B2-Zoomed-300x170.jpg 300w, https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/AHER-2007-US7186842B2-Zoomed-1024x581.jpg 1024w, https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/AHER-2007-US7186842B2-Zoomed-768x436.jpg 768w, https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/AHER-2007-US7186842B2-Zoomed-1536x872.jpg 1536w, https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/AHER-2007-US7186842B2-Zoomed-2048x1163.jpg 2048w, https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/AHER-2007-US7186842B2-Zoomed-700x397.jpg 700w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a>Donepezil hydrochloride API is unstable.\u00a0 This limits finished dosage form stability and impacts product distribution.<\/p>\n<p style=\"text-align: justify;\">Responding to this need, USV, Ltd., a leading bulk API manufacturer, developed a more-stable polymorph for this API.\u00a0 To protect this new product, USV filed <a href=\"https:\/\/licensinglaw.net\/blog3\/?page_id=818\">WO 2006\/011154<\/a>.\u00a0 The appurtenant search report, however, revealed troubling news: Dr. Reddy\u2019s Laboratories, another leading bulk API manufacturer, had also found this more-stable polymorph \u2013 and filed a patent application 15 months before USV.\u00a0 News of DRL\u2019s earlier patent application (<a href=\"https:\/\/licensinglaw.net\/blog3\/?page_id=826\">US 2004 \/ 00229914<\/a>) was troubling for two reasons: it implied that USV could not get a patent, and it raised the risk that DRL might get a patent blocking USV\u2019s product from the market entirely.\u00a0 <a href=\"https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/REDDY-2004-US2004229914A1-Zoomed.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignright wp-image-839 size-medium\" src=\"https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/REDDY-2004-US2004229914A1-Zoomed-204x300.jpg\" alt=\"\" width=\"204\" height=\"300\" srcset=\"https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/REDDY-2004-US2004229914A1-Zoomed-204x300.jpg 204w, https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/REDDY-2004-US2004229914A1-Zoomed.jpg 618w\" sizes=\"auto, (max-width: 204px) 100vw, 204px\" \/><\/a><\/p>\n<p style=\"text-align: justify;\">USV asked us to help.\u00a0 In response, we designed and successfully executed a strategy which won USV a patent, and did so quickly, while the earlier-filed DRL application languished in the Patent Office.\u00a0 Further, we assured that USV\u2019s patent preempted DRL\u2019s planned product.<\/p>\n<p style=\"text-align: justify;\"><a href=\"https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/1.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft wp-image-830 size-thumbnail\" src=\"https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/1-150x150.jpg\" alt=\"\" width=\"150\" height=\"150\" srcset=\"https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/1-150x150.jpg 150w, https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/1-298x300.jpg 298w, https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/1-1018x1024.jpg 1018w, https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/1-768x773.jpg 768w, https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/1-1527x1536.jpg 1527w, https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/1-432x432.jpg 432w, https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/1-268x268.jpg 268w, https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/1-700x704.jpg 700w, https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/1.jpg 1972w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/a>The upshot: we overcame a 15 month filing date disadvantage to win a patent which both negated a threat of infringement liability and blocked a formidable competitor\u2019s planned product.\u00a0 This is what we call \u201cF2O Prosecution\u201d: two benefits in one.<\/p>\n<p style=\"text-align: justify;\">To find out how we may help you overcome third-party applications, <a href=\"https:\/\/licensinglaw.net\/blog3\/?page_id=22\">Contact Us<\/a>.<\/p>\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Have you identified a pending third party patent application which threatens to derail an important new product launch?\u00a0 Perhaps we can help twice over, negating the legal threat of infringement while also increasing your market share.\u00a0 We call this \u201cF2O Prosecution\u201d because it fills two goals at once \u2013 providing &#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":11,"menu_order":1,"comment_status":"closed","ping_status":"closed","template":"template-full-width.php","meta":{"footnotes":""},"class_list":["post-212","page","type-page","status-publish","hentry","column","twocol"],"_links":{"self":[{"href":"https:\/\/licensinglaw.net\/blog3\/index.php?rest_route=\/wp\/v2\/pages\/212","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/licensinglaw.net\/blog3\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/licensinglaw.net\/blog3\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/licensinglaw.net\/blog3\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/licensinglaw.net\/blog3\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=212"}],"version-history":[{"count":26,"href":"https:\/\/licensinglaw.net\/blog3\/index.php?rest_route=\/wp\/v2\/pages\/212\/revisions"}],"predecessor-version":[{"id":843,"href":"https:\/\/licensinglaw.net\/blog3\/index.php?rest_route=\/wp\/v2\/pages\/212\/revisions\/843"}],"up":[{"embeddable":true,"href":"https:\/\/licensinglaw.net\/blog3\/index.php?rest_route=\/wp\/v2\/pages\/11"}],"wp:attachment":[{"href":"https:\/\/licensinglaw.net\/blog3\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=212"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}